It was approved in combination with the selective ER degrader fulvestrant for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative and PI3Kα-mutated breast cancer at an advanced or metastatic stage in 2019 [187]. Here, ERBB2 is linked to breast cancer.